Atomoxetine plus oxybutynin improves multiple variables in OSA

A nightly, 30-day atomoxetine and oxybutynin (80/5 mg) regimen lowered baseline OSA hypoxic burden by ∼50% as measured by the Apnea-hypopnea Index with 4% oxygen desaturation (AHI4), in a randomized trial involving 39 participants. The combination was well tolerated, with generally mild adverse effects consistent with the known side-effect profiles of the individual drugs.